Exane BNP Paribas initiated coverage of AstraZeneca with a rating of Outperform and set a new price target of $75.00

UBS upgraded AstraZeneca from Neutral to Buy

Morgan Stanley initiated coverage of AstraZeneca with a rating of Overweight

UBS upgraded AstraZeneca from Sell to Neutral

Deutsche Bank upgraded AstraZeneca from Sell to Hold

Deutsche Bank downgraded AstraZeneca from Hold to Sell

Goldman initiated coverage of AstraZeneca with a rating of Buy and set a new price target of $97.00

Deutsche Bank upgraded AstraZeneca from Sell to Hold

Deutsche Bank downgraded AstraZeneca from Hold to Sell

Morgan Stanley initiated coverage of AstraZeneca with a rating of Overweight and set a new price target of $85.00

FLAURA2 final overall survival analysis reinforces the favorable benefit-risk profile of this combination Results underscore TAGRISSO as 1st-line standard of care and backbone therapy in EGFRm lung cancer across stages Positive results from the final overall survival (OS) analysis of the FLAURA2 Phase III trial showed AstraZeneca's TAGRISSO® (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the key secondary endpoint of OS compared to TAGRISSO monotherapy in the 1st-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) no

Baxdrostat 2mg lowered systolic blood pressure by 15.7 mmHg (9.8 mmHg placebo-adjusted) from baseline, and was generally well tolerated with no unanticipated safety findings Full results presented at the European Society of Cardiology Congress 2025 and published in the New England Journal of Medicine Positive full results from the ​BaxHTN Phase III trial showed ​baxdrostat demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure (SBP) at two doses (2mg and 1mg) compared with placebo at 12 weeks. Results were seen in patients with hard-to-control (uncontrolled and resistant) hypertension who received baxdrostat or placebo on top

AstraZeneca launches the first FDA-approved influenza vaccine available for self- or caregiver administration, providing a convenient, household-based option for seasonal flu vaccination AstraZeneca today launches FluMist Home, the first-of-its-kind, at-home delivery service for FLUMIST® (Influenza Vaccine Live, Intranasal). FLUMIST is the first and only seasonal influenza vaccine approved to be self-administered by adults 18 to 49 years of age or administered by a parent or caregiver to individuals 2-17 years of age.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250815310613/en/ Initially approved by the Food and Drug Admin

The HBA's ACE Awards spotlight bold, people-first programs that are transforming how the industry develops, engages, and empowers its workforce. FAIRFIELD, N.J., Aug. 13, 2025 /PRNewswire/ -- The Healthcare Businesswomen's Association (HBA) today announced the recipients of its 2025 Advancement, Commitment, and Engagement (ACE) Awards, honoring high-impact programs that are redefining workforce development across the healthcare industry. The ACE Awards recognize standout programs with bold strategies that prioritize people, scale globally, deliver measurable business and social outcomes, and honor the future of leadership and innovation in healthcare. This year's honorees include:

The agreement is a critical step in ensuring adult patients living with NMOSD and gMG have public access to Ultomiris MISSISSAUGA, ON, Aug. 7, 2025 /CNW/ - Alexion Pharma Canada Corp., AstraZeneca's Rare Disease group, has entered into a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for Ultomiris (ravulizumab) for the treatment of adult patients with anti-aquaporin 4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD) and adult patients with anti-acetylcholine receptor (AChR) antibody-positive (Ab+) generalized myasthenia gravis (gMG). With the agreement in place with the pCPA, individual provinces and territories may now initiate the p

BOSTON and ROLLE, Switzerland, Aug. 5, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an expansion of its partnership with AstraZeneca (NASDAQ:AZN). This new, multi-year collaboration will leverage SOPHiA GENETICS's multimodal AI Factories to generate evidence on the efficacy, value, and real-world impact of therapies for certain types of breast cancer. It will also support the potential development of a bespoke AI-powered predictive model aimed at optimizing outcomes for individuals undergoing treatment for breast cancer.

Strong growth momentum continues with excellent R&D pipeline delivery in the year-to-date AstraZeneca: Revenue and EPS summary   H1 2025 % Change Q2 2025 % Change   $m Actual CER1 $m Actual CER - Product Sales 26,670 8 10 13,795 11 10 - Alliance Revenue 1,293 38 38 654 36 35 Product Revenue2 27,963 9 11 14,449 12 11 Collaboration Revenue 82 68 66 8 >2x >2x Total Revenue 28,045 9 11 14,457 12 11

Based on MATTERHORN Phase III trial results which demonstrated a statistically significant and clinically meaningful event-free survival benefit If approved, this will be the first and only perioperative immunotherapy-based regimen in this setting AstraZeneca's supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) has been accepted and granted Priority Review in the US for the treatment of patients with resectable, early-stage and locally advanced (Stages II, III, IVA) gastric and gastroesophageal junction (GEJ) cancers. The Food and Drug Administration (FDA) grants Priority Review to applications for medicines that, if approved, would offer significant improveme

Investment will support AstraZeneca's ambition to reach $80 billion revenue by 2030, with 50% generated in the US Cornerstone of investment is a proposed new multi-billion dollar drug substance manufacturing center focused on chronic diseases in the Commonwealth of Virginia, the Company's largest single investment in a facility to date AstraZeneca today announces $50 billion of investment in the United States by 2030, building on America's global leadership in medicines manufacturing and R&D. This investment is expected to create tens of thousands of new, highly skilled direct and indirect jobs across the country powering growth and delivering next generation medicines for patients in A

Longer-term follow up in the FLAURA2 Phase III trial confirms the favorable benefit-risk profile of this combination Overall survival results reinforce TAGRISSO as the backbone therapy in EGFRm lung cancer across stages Positive high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase III trial showed AstraZeneca's TAGRISSO® (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the key secondary endpoint of OS compared to TAGRISSO monotherapy for patients with 1st-line locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-sm

6-K - ASTRAZENECA PLC (0000901832) (Filer)

6-K - ASTRAZENECA PLC (0000901832) (Filer)

6-K - ASTRAZENECA PLC (0000901832) (Filer)

6-K - ASTRAZENECA PLC (0000901832) (Filer)

6-K - ASTRAZENECA PLC (0000901832) (Filer)

6-K - ASTRAZENECA PLC (0000901832) (Filer)

6-K - ASTRAZENECA PLC (0000901832) (Filer)

6-K - ASTRAZENECA PLC (0000901832) (Filer)

6-K - ASTRAZENECA PLC (0000901832) (Filer)

6-K - ASTRAZENECA PLC (0000901832) (Filer)

ROCKVILLE, Md., June 6, 2024  /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced the appointment of Dr. Phillip Dennis as Chief Medical Officer. Dr. Dennis, who will join I-Mab effective June 17, 2024, will lead the Company's global clinical development efforts and serve as a member of I-Mab's Executive Leadership Team. "I am pleased to welcome Dr. Phillip Dennis as our Chief Medical

In recognition of Rare Disease Day on February 29, Alexion welcomes people across the country to join the international colourUp4RARE challenge and learn more about the impact of rare diseases on an estimated three million Canadian families MISSISSAUGA, ON, Feb. 26, 2024 /CNW/ - Alexion Pharma Canada Corp., AstraZeneca's Rare Disease group, is marking Rare Disease Day on February 29 by launching colourUp4RARE. The international campaign aims to raise awareness of how to improve quality of life of people living with rare diseases in Canada, and around the world. Approximately,

NIH data show that globally less than 2% of genetic information being studied today originates from people of African ancestry1 The newly established Diaspora Human Genomics Institute (DHGI) will manage the Together for CHANGE initiative, which aims to increase available genomic data for people of African ancestry and enhance representation in STEM careers NASHVILLE, Tenn. and TARRYTOWN, N.Y. and WILMINGTON, Del. and BAGSVAERD, Denmark and BASEL, Switzerland, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Meharry Medical College, along with partners Regeneron Genetics Center® (RGC™), AstraZeneca, Novo Nordisk, and Roche, today announced the launch of the Together for CHANGE™ ("Changing Healthcare for

Cristian Massacesi, M.D., Appointed to Replay Board of Directors Cristian Massacesi, M.D., Chief Medical Officer of AstraZeneca and Alexion and Oncology Chief Development Officer of AstraZeneca, to support Replay in advancing genomic medicine and cell therapy pipelineDr. Massacesi brings over 20 years of research and medicines development experience to the Replay Board San Diego, California and London, UK, May 25, 2023 – Replay, a genome writing company reprogramming biology by writing and delivering big DNA, today announced the appointment of Cristian Massacesi, M.D., as a member of its Board of Directors, with immediate effect. Dr. Massacesi is a leading expert in medical oncology, wi

SC 13G/A - ASTRAZENECA PLC (0000901832) (Subject)

SC 13G/A - ASTRAZENECA PLC (0000901832) (Subject)

Baxdrostat 2mg lowered systolic blood pressure by 15.7 mmHg (9.8 mmHg placebo-adjusted) from baseline, and was generally well tolerated with no unanticipated safety findings Full results presented at the European Society of Cardiology Congress 2025 and published in the New England Journal of Medicine Positive full results from the ​BaxHTN Phase III trial showed ​baxdrostat demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure (SBP) at two doses (2mg and 1mg) compared with placebo at 12 weeks. Results were seen in patients with hard-to-control (uncontrolled and resistant) hypertension who received baxdrostat or placebo on top

Strong growth momentum continues with excellent R&D pipeline delivery in the year-to-date AstraZeneca: Revenue and EPS summary   H1 2025 % Change Q2 2025 % Change   $m Actual CER1 $m Actual CER - Product Sales 26,670 8 10 13,795 11 10 - Alliance Revenue 1,293 38 38 654 36 35 Product Revenue2 27,963 9 11 14,449 12 11 Collaboration Revenue 82 68 66 8 >2x >2x Total Revenue 28,045 9 11 14,457 12 11

Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo Positive high-level results from the BaxHTN Phase III trial showed baxdrostat at two doses (2mg and 1mg) demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure (SBP) compared with placebo at 12 weeks. The trial also successfully met all secondary endpoints. Patients with uncontrolled or treatment resistant hypertension received baxdrostat or placebo on top of standard of care. Baxdrostat was generally well tolerated with a favorable safety profile. There are 1.3 billion people worldwide livin

Growth momentum and pipeline delivery set AstraZeneca on a strong trajectory towards 2030 ambition AstraZeneca: Revenue and EPS summary   Q1 2025 % Change       $m Actual CER1       - Product Sales 12,875 6 9       - Alliance Revenue 639 40 42       Product Revenue2 13,514 7 10       Collaboration Revenue 74 64 64       Total Revenue 13,588 7 10       Reported EPS ($) 1.88 34 32       Core3 EPS ($) 2.49 21 21       Key performance elements for Q1 2025 (Growth numbers at constant exchange

STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to

Strong momentum in FY 2024 with Total Revenue and Core EPS up 21% and 19% respectively AstraZeneca: Revenue and EPS summary     FY 2024 % Change Q4 2024 % Change $m Actual CERi $m Actual CER - Product Sales 50,938 16 19 13,362 18 19 - Alliance Revenue   2,212 55 55 714 68 69 - Collaboration Revenue 923 56 54 815 >2x >2x Total Revenue   54,073 18 21 14,891 24 25 Reported EPS $4.54 18 29

Upgrade to full year 2024 guidance underpinned by strong underlying growth momentum AstraZeneca: Revenue and EPS summary     9M 2024 % Change Q3 2024 % Change $m Actual CER1 $m Actual CER - Product Sales 37,576 16 19 12,947 18 20 - Alliance Revenue   1,498 49 50 559 48 50 - Collaboration Revenue 108 (66) (66) 59 (39) (40) Total Revenue   39,182 16 19 13,565 18 21 Reported EPS $3.57 11 21

ODD and RPDD granted by the FDA and ODD granted by the European Commission to UCART22 for the treatment of ALLODD granted by the FDA to CLLS52 (alemtuzumab) for ALL treatmentCash position of $273 million as of June 30, 20241; cash runway projection into 2026 NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today provided business updates and reported financial results for the six-month period ending June 30, 2024. "Over the past months, we have achieved a significant milestone with the granting of ODD designations by

Strong underlying growth supports FY 2024 guidance upgrade, with both Total Revenue and Core EPS now expected to increase by a mid teens percentage at CER1 AstraZeneca: Revenue and EPS summary H1 2024 % Change   Q2 2024 % Change $m Actual CER   $m Actual CER - Product Sales 24,629 15 18   12,452 14 18 - Alliance Revenue   939 50 50   482 42 42 - Collaboration Revenue 49 (78) (78)   4 (98) (98) Total Revenue   25,617 15 18   12,938 13 17

•  Cellectis announced completion of the additional equity investment of $140M by AstraZeneca •  Cash position of $143 million as of March 31, 20241; cash runway projection into 20262 •  Conference call and webcast scheduled for tomorrow, May 29, 2024 at 8:00AM ET / 2:00PM CET NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today provided business updates and reported financial results for the three-month period ending March 31, 2024. "We are thrilled to have announced the closing of the additional equity investment of $14